“Ra-SBRT Is Potential Immune Adjuvant for Innate Immune Cell Populations in Advance Stage NSCLC Patients ”. 2019. Journal of Analytical Oncology 8 (November): 71-76. https://doi.org/10.30683/1927-7229.2019.08.10.